<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473108</url>
  </required_header>
  <id_info>
    <org_study_id>13786</org_study_id>
    <secondary_id>2010-018500-90</secondary_id>
    <nct_id>NCT01473108</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862</brief_title>
  <official_title>Study to Investigate the Effectiveness of Different Single Oral Doses of BAY94-8862 on Natriuresis After Administration of 0.5 mg Fludrocortisone (Astonin H®) With 50 mg Eplerenone (Inspra®) as Active Control in Healthy Male Subjects in a Randomized, Single-blind, Placebo-controlled, Combined 3-fold Crossover and Parallel-group Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacodynamics, pharmacokinetics, safety, and tolerability will be investigated in this
      single dose study. In 5 treatment groups, different dosages of BAY94-8862 will be given in
      healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical pharmacology
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Log10 (10*urinary Na+/K+ ratio)</measure>
    <time_frame>Up to 26 hours post-dose</time_frame>
    <description>Parameter for natriuresis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>Up to 60 hours after administration</time_frame>
    <description>Area under the concentration vs time curve from zero to infinity after single (first) dose for both BAY 94-8862 and eplerenone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 60 hours after administration</time_frame>
    <description>Maximum observed drug concentration in measured matrix after single dose administration for both BAY 94-8862 and eplerenone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Pharmacology, Clinical</condition>
  <arm_group>
    <arm_group_label>Finerenone (20 mg solution)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-fold crossover of single dose 20 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finerenone (10 mg solution)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-fold crossover of single dose 10 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finerenone (5 mg solution)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-fold crossover of single dose 5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finerenone (20 mg as tablets)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-fold crossover of single dose 20 mg BAY 94-8862 as 2 x 10 mg tablet, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Finerenone (2.5 mg solution)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-fold crossover of single dose 2.5 mg BAY 94-8862 solution, placebo and 50 mg eplerenone. The challenge drug fludrocortisone was given 2 h prior to administration of BAY 94-8862, eplerenone, and placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finerenone (BAY 94-8862) PEG solution</intervention_name>
    <description>2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862</description>
    <arm_group_label>Finerenone (20 mg solution)</arm_group_label>
    <arm_group_label>Finerenone (10 mg solution)</arm_group_label>
    <arm_group_label>Finerenone (5 mg solution)</arm_group_label>
    <arm_group_label>Finerenone (2.5 mg solution)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finerenone (BAY 94-8862) immediate release tablet</intervention_name>
    <description>20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets</description>
    <arm_group_label>Finerenone (20 mg as tablets)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone (Inspra®)</intervention_name>
    <description>Single oral dose of 50 mg eplerenone</description>
    <arm_group_label>Finerenone (20 mg solution)</arm_group_label>
    <arm_group_label>Finerenone (10 mg solution)</arm_group_label>
    <arm_group_label>Finerenone (5 mg solution)</arm_group_label>
    <arm_group_label>Finerenone (20 mg as tablets)</arm_group_label>
    <arm_group_label>Finerenone (2.5 mg solution)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step</description>
    <arm_group_label>Finerenone (20 mg solution)</arm_group_label>
    <arm_group_label>Finerenone (10 mg solution)</arm_group_label>
    <arm_group_label>Finerenone (5 mg solution)</arm_group_label>
    <arm_group_label>Finerenone (20 mg as tablets)</arm_group_label>
    <arm_group_label>Finerenone (2.5 mg solution)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male white subjects

          -  18 to 46 years of age

          -  Body mass index (BMI): 18 - 29.9 kg/m²

        Exclusion Criteria:

          -  Clinically relevant findings in medical history or in the physical examination

          -  Systolic blood pressure below 100 or above 140 mmHg

          -  Diastolic blood pressure below 50 or above 90 mmHg

          -  Heart rate below 45 or above 95 beats / min
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>46 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Neuss</city>
        <state>Nordrhein-Westfalen</state>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe.</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2011</study_first_submitted>
  <study_first_submitted_qc>November 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers, proof-of-concept trial, PK and PD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Fludrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

